Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Research Letter
  • Published:

Hypertension in an urban population – who is treated with what and how well?

Journal of Human Hypertension volume 21, pages 323–326 (2007)Cite this article

This study investigated the profile of long-term blood pressure (BP)-lowering medication in a population-based cohort, and whether treatment effects on BP control or risk of cardiovascular disease (CVD) differed between the types or patterns of BP-lowering regimes. In treated hypertensive patients, only 11.3% had a BP<140/90 mm Hg. Inadequate drug combination and underestimation of global risk score seemed to be the possible reasons for poor BP control. Neither CVD morbidity nor mortality showed any significant difference in relation to treatment types or patterns.

Beneficial effects of BP-lowering medication on preventing CVD are well established. Diuretics and β-blockers have been recommended as basic antihypertensive agents.1 Newly developed pharmacologic BP-lowering agents provide additional choice. Little is known about the profile of long-term BP-lowering medication in a community-based setting and the effects of different types of treatment on BP control or CVD risk.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo Jr JL et al. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 2003; 42: 1206–1252.

    Article  CAS  Google Scholar 

  2. Berglund G, Elmståhl S, Janzon, Larsson SA . Design and feasibility. J Intern Med 1993; 233: 45–51.

    Article  CAS  Google Scholar 

  3. Li C, Engström G, Hedblad B, Janzon L . Sex-specific cardiovascular morbidity and mortality in a cohort treated for hypertension. J Hypertens 2006; 24: 1523–1529.

    Article  CAS  Google Scholar 

  4. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB . Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97: 1837–1847.

    Article  CAS  Google Scholar 

  5. Wolf-Maier K, Cooper RS, Kramer H, Banegas JR, Giampaoli S, Joffres MR et al. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension 2004; 43: 10–17.

    Article  CAS  Google Scholar 

  6. Persson M, Carlberg B, Tavelin B, Lindholm LH . Doctors' estimation of cardiovascular risk and willingness to give drug treatment in hypertension: fair risk assessment but defensive treatment policy. J Hypertens 2004; 22: 65–71.

    Article  CAS  Google Scholar 

  7. Cuspidi C, Michev I, Lonati L, Vaccarella A, Cristofari M, Garavelli G et al. Compliance to hypertension guidelines in clinical practice: a multicentre pilot study in Italy. J Hum Hypertens 2002; 16: 699–703.

    Article  CAS  Google Scholar 

  8. Turnbull F . Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomized trials. Lancet 2003; 362: 1527–1535.

    Article  CAS  Google Scholar 

  9. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995–1003.

    Article  CAS  Google Scholar 

  10. Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, de Faire U et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lance 2002; 359: 1004–1010.

    Article  CAS  Google Scholar 

  11. Jones JK, Gorkin L, Lian JF, Staffa JA, Fletcher AP . Discontinuation of and changes in treatment after start of new courses of antihypertensive drugs: a study of a United Kingdom population. BMJ 1995; 311: 293–295.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical Science, Epidemiological Research Group, Malmö University Hospital, Malmö, Sweden

    C Li, B Hedblad & L Janzon

  2. Department of Clinical Sciences in Malmö, Internal Medicine Research Group, University Hospital, Malmö, Sweden

    G Berglund

Authors
  1. C Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. B Hedblad
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. G Berglund
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. L Janzon
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C Li.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Li, C., Hedblad, B., Berglund, G. et al. Hypertension in an urban population – who is treated with what and how well?. J Hum Hypertens 21, 323–326 (2007). https://doi.org/10.1038/sj.jhh.1002142

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.jhh.1002142

Search

Advanced search

Quick links